Gene · 2053
Papers2,484
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,484
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Novel dual inhibitor targeting FAAH and sEH: Design, synthesis, and in-vitro evaluation of oxadiazole analogues. | Mol Divers | 2026 | 40622672 | PubTator, text mining | PubMed |
| Regulation of P450-derived epoxy fatty acids in cardiovascular diseases. | Redox Biochem Chem | 2025 | 42006847 | PubTator, text mining | PubMed |
| Decoding the cholesterol-apoptosis axis in HCC: a machine learning-based multi-omics integration and single-cell transcriptomic analysis. | Discov Oncol | 2025 | 41288805 | PubTator, text mining | PubMed |
| Oxylipins in Atherosclerosis: Their Role in Inflammation, Diagnosis, and Therapeutic Perspectives. | Int J Mol Sci | 2025 | 41226613 | PubTator, text mining | PubMed |
| Probing the selectivity of urea, amide, and amine-based EPHX2 inhibitors towards EPHX1 and EPHX3: A computational study. | Comput Biol Med | 2025 | 41223648 | PubTator, text mining | PubMed |
| Regulating arachidonic acid metabolism: a novel strategy to prevent colorectal inflammatory cancer transformation. | J Cancer | 2025 | 41210682 | PubTator, text mining | PubMed |
| Mechanistic insights into the delayed yellowing of broccoli by the combination of ectoine and lactide peptide. | NPJ Sci Food | 2025 | 41203678 | PubTator, text mining | PubMed |
| Developments in small-molecule soluble epoxide hydrolase inhibitors: synthetic advances and therapeutic applications. | Future Med Chem | 2025 | 41170709 | PubTator, text mining | PubMed |
Bioactive constituents isolated from the leaves of Phyllostachys Bambusoides with potent soluble epoxide hydrolase inhibitory activity: enzyme kinetics, molecular docking, and molecular dynamics simulations. | J Comput Aided Mol Des | 2025 | 41136865 | PubTator, text mining | PubMed |
| Bioinformatics analyses of comorbid mechanisms between psoriasis and type 2 diabetes mellitus. | Sci Rep | 2025 | 41120603 | PubTator, text mining | PubMed |
| Click chemistry enables rapid development of potent sEH PROTACs using a direct-to-biology approach. | Chem Commun (Camb) | 2025 | 41120092 | PubTator, text mining | PubMed |
Metabolic and vascular contributions to dementia: Soluble epoxide hydrolase-derived linoleic acid oxylipins and glycemic status are related to cerebral small vessel disease markers, atrophy, and cognitive performance. | Alzheimers Dement | 2025 | 41059602 | PubTator, text mining | PubMed |
| Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease and Other Neurological Disorders: A Comprehensive Review. | Biomedicines | 2025 | 41007636 | PubTator, text mining | PubMed |
| Omics characteristics and epigenetic modifications of adipose-derived stem cells. | J Biol Chem | 2025 | 41005477 | PubTator, text mining | PubMed |
| Putative receptors and signaling pathways responsible for the biological actions of epoxyeicosatrienoic acids. | J Biol Chem | 2025 | 40975174 | PubTator, text mining | PubMed |
| Harnessing structure-activity relationships to repurpose the FLAP inhibitor BRP-7 into potent and selective sEH inhibitors. | Bioorg Chem | 2025 | 40974655 | PubTator, text mining | PubMed |
| Development of Potent and Selective Dual PPARδ/sEH Modulators from an AI-Designed Scaffold. | J Med Chem | 2025 | 40966045 | PubTator, text mining | PubMed |
| Novel Triazole-Linked Indole Derivatives as Potent Soluble Epoxy Hydrolase Inhibitors With Promising Anticancer Activity. | Chem Biol Drug Des | 2025 | 40899519 | PubTator, text mining | PubMed |
| Arachidonic acid metabolism in metabolic dysfunction-associated steatotic liver disease and liver fibrosis. | Hepatol Commun | 2025 | 40879475 | PubTator, text mining | PubMed |
| Targeted soluble epoxide hydrolase inhibits M1 macrophage polarization to improve cartilage injury in temporomandibular joint osteoarthritis. | J Transl Med | 2025 | 40877980 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2053/papers?page=5